Contact us for more information

I want to be contacted
STEP Digital and Biotechnology | Business Research, Development and Innovation

STEP Digital and Biotechnology | Business Research, Development and Innovation

Opened Until 30-04-2026

The Business Research, Development and Innovation Incentive System – STEP (Digital and Biotechnology) aims to support integrated operations that combine R&D activities with productive investment under a co-promotion regime. The focus lies on the development of critical technologies (such as advanced AI, quantum computing, and gene therapies) and the strengthening of their value chains. This programme, part of the STEP Platform, seeks to raise technological readiness levels (TRL) from industrial research to commercial production (TRL 4 to 9), ensuring technological leadership and the reduction of the European Union's strategic dependencies.

  • Intervention Type
    Business Research, Development and Innovation Incentive System
  • Beneficiaries
    Micro, Small and Medium-sized Enterprises (SMEs), Large Companies (Non-SMEs) and ENESII
  • Regional Scope
    North, Centre, Alentejo, Algarve
  • Support Rate
    Up to 80% Non-repayable Grant

Actions covered by notice MPr-2026-2

Operations must focus on innovative developments that contribute to European autonomy in two fundamental sectors:

  • Digital Technologies and Deep Tech: Focus on artificial intelligence, 5G/6G, quantum computing, advanced semiconductors, cybersecurity, and autonomous robotics.
  • Biotechnologies: Manufacturing of critical medicines, genetic engineering (DNA/RNA), cellular therapies, bioinformatics, and nanobiotechnology.

Operation Types 

The central operation type is the Integrated Investment in Business Research, Development and Innovation (RDI) under a Co-promotion regime. Operations must mandatorily include:

  • R&D Activities: Industrial research and experimental development for the creation of new products or processes.
  • Complementary Productive Investment: Productive innovation actions aimed at bringing R&D results to the market, including:
      -  Creation of new establishments;
      -  Diversification of activity or production;
      -  Fundamental change of the production process.

Projects must aim for the manufacture of:

  • Final products in the field of critical digital or biotechnological technologies;
  • Specific components and machinery for this manufacturing;
  • Critical raw materials and specialised associated services (e.g. clean rooms, edge cloud services).

Investment Types

Eligibility is divided into two main components with distinct rules:

A - Research and Development (R&D) Component

  • Costs for technical personnel and salary expenses;
  • Raw materials, consumable materials, and components for prototypes;
  • Acquisition of patents and scientific consultancy services;
  • Instruments and technical-scientific equipment;
  • Indirect Costs: Flat rate of 7% on direct costs;

B - Productive Innovation Component

  • Tangible assets (machinery, equipment, and hardware);

  • Intangible assets (technology transfer and patents - 50% limit for Large Companies);
  • Construction of buildings and refurbishment works (limit of 20% of the productive component, or 40% in the Algarve);
  • Engineering services and certifications (exclusive to SMEs).

Application Dates

  • Start: 30/01/2026.
  • End: 30/04/2026 (until 17:00).

Notice Beneficiaries

The tender requires the formation of complete consortia necessarily led by a company.

Company Types

  • SMEs (Micro, Small, and Medium-sized Enterprises);
  • Small Mid-Caps: Companies that are not SMEs but have up to 499 employees and a turnover ≤ €100M (or balance sheet ≤ €86M);
  • Large Companies: Companies that exceed Small Mid-Cap limits.
  • ENESII: Universities, polytechnic institutes, and technology interface centres (including those from Autonomous Regions if in partnership with promoters from the Mainland).

Consortium Rules

  • Maximum of 10 beneficiaries per consortium.
  • Companies must assume the majority financial weight of the project.
  • The consortium leader must necessarily invest in both R&D and Productive Innovation.

Financing and Support Rates

Support is granted in the form of a Grant (Non-repayable), calculated based on actual eligible costs.

Budgetary Allocation per programme

The global allocation of €153,000,000 is distributed as follows:

  • COMPETE 2030 (PITD): €150,000,000 (one hundred and fifty million euros)
  • Algarve 2030: €3,000,000 (three million euros)

Financing Rates (Aid Intensity)

1. R&D Component (Research Activities)

Financing rates apply to actual costs and depend on the nature of the research:

  • Base Rate:

    • Industrial Research (TRL 4): 50%

    • Experimental Development (TRL 5-7): 25%

  • Bonuses (Cumulative up to a limit of 80%):

    • Company Size: +10 p.p. for Medium Enterprises; +20 p.p. for Micro and Small Enterprises.

    • Collaboration or Dissemination: +15 p.p. if there is effective collaboration between companies or with ENESII, or wide dissemination of results.

    • Location: +15 p.p. or +5 p.p. for projects developed in regions classified as other territories.

      Note: Collaboration and Location bonuses are not cumulative with each other.

  • ENESII: Maximum rate of 85%, provided the activities are of a non-economic nature.

2. Productive Innovation Component (Industrial Investment)

This component follows the Regional Aid Map (STEP), with increased intensities:

  • Micro and Small Enterprises: Between 60% and 70% (depending on the NUTS III sub-region).
  • Medium Enterprises: Between 50% and 60%.
  • Large Companies and Small Mid-Caps: Between 40% and 50%.

In the case of the Algarve, the limits described above are only applicable if the project location is classified as a low-density territory; otherwise, the de minimis regime or reduced rates up to a maximum of 20% apply.

Financing Conditions

  • Minimum Investment: €5,000,000 (five million euros) — this limit does not apply in the Algarve region.
  • Maximum Investment: €25,000,000 (twenty-five million euros).
  • Project Duration: 36 months

Note: The company must prove that the new investment is relevant compared to its existing assets. The investment must represent at least 10% of its current Net Fixed Assets.

Pedir mais informações sobre STEP Digital and Biotechnology | Business Research, Development and Innovation